GlassScriptPhysician profile
Synthia L Frank
NPI 1902428386
$2,754.66
in general payments reported to CMS, 2019-2025
29 companies · $978 in 2025
The $978 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $618 · 2024: $945 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.13 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.76 | 2022-2025 | |
| Axsome Therapeutics, INC. | $427.74 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $294.55 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $268.86 | 2022-2025 | Mounjaro, Emgality, Zepbound |
| Corcept Therapeutics | $241.50 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $142.26 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.42 | 2022-2025 | Caplyta |
| Amgen INC. | $79.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $77.64 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $65.09 | 2024 | |
| Glaxosmithkline, LLC. | $63.38 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $60.48 | 2025 | Fanapt |
| Alkermes, INC. | $54.20 | 2022-2024 | Lybalvi |
| Regeneron Healthcare Solutions, INC. | $53.07 | 2024-2025 | Dupixent |
| Lundbeck LLC | $48.05 | 2023-2025 | Vyepti, Abilify Maintena |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36.90 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $30.96 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2022-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $24.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2024 | Farxiga |
| Hologic Sales and Service, LLC | $21.97 | 2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $18.50 | 2022 | |
| Viatris Specialty LLC | $16.23 | 2025 | Yupelri |
| Astellas Pharma US INC | $15.67 | 2025 | Veozah |
| Exact Sciences Corporation | $14.39 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $13.95 | 2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $13.48 | 2025 | Jornay Pm |
| Corium, LLC | $13.41 | 2022 | |
| Sumitomo Pharma America, INC. | $10.38 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Synthia Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.